GOVXW
Get informed when a big investor buys or sells
+ FollowUndervalued by 22200% based on the discounted cash flow analysis.
| Market cap | $652,909.00 |
|---|---|
| Enterprise Value | $-2,167,372.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-22.4 |
| Beta | 3.57 |
| Outstanding Shares | 4,565,207 |
| P/E Ratio | -0.05 |
|---|---|
| PEG | 0.28 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.1 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.15 |
| Debt to Equity | 0.18 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this pl...